Table 1.

Characteristics of hemophilic subjects with cleared and chronic HCV infection




HCV cleared, no. (%)

HCV chronic, no. (%)

P
Ancestry    
   African   16 (19.1)   68 (80.9)   
   Non-African   176 (28.0)   452 (72.0)   .08  
Sex    
   Male   183 (27.3)   488 (72.7)   
   Female   9 (22.0)   32 (78.0)   .46  
Type of coagulation deficiency    
   Hemophilia A   141 (28.5)   353 (71.5)   
   Hemophilia B   40 (26.0)   114 (74.0)   
   Other   11 (17.2)   53 (82.8)   .15  
Severity of coagulation deficiency    
   Mild   34 (20.5)   132 (79.5)   
   Moderate   31 (25.2)   92 (74.8)   
   Severe   127 (30.0)   296 (70.0)   .06  
Type of factor treatment*    
   NHT only or first   65 (30.2)   150 (69.8)   
   Both, cryo/plasma first   78 (27.5)   206 (72.5)   
   Cryo/plasma only
 
32 (24.6)
 
98 (75.4)
 
.52
 



HCV cleared, no. (%)

HCV chronic, no. (%)

P
Ancestry    
   African   16 (19.1)   68 (80.9)   
   Non-African   176 (28.0)   452 (72.0)   .08  
Sex    
   Male   183 (27.3)   488 (72.7)   
   Female   9 (22.0)   32 (78.0)   .46  
Type of coagulation deficiency    
   Hemophilia A   141 (28.5)   353 (71.5)   
   Hemophilia B   40 (26.0)   114 (74.0)   
   Other   11 (17.2)   53 (82.8)   .15  
Severity of coagulation deficiency    
   Mild   34 (20.5)   132 (79.5)   
   Moderate   31 (25.2)   92 (74.8)   
   Severe   127 (30.0)   296 (70.0)   .06  
Type of factor treatment*    
   NHT only or first   65 (30.2)   150 (69.8)   
   Both, cryo/plasma first   78 (27.5)   206 (72.5)   
   Cryo/plasma only
 
32 (24.6)
 
98 (75.4)
 
.52
 
*

Non-heat-treated (NHT) factor concentrate; cryoprecipitate or fresh-frozen plasma (cryo/plasma) used first (before the other) or exclusively

Close Modal

or Create an Account

Close Modal
Close Modal